TIDAL-01 is under clinical development by Turnstone Biologics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TIDAL-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TIDAL-01 is under development for the treatment of solid tumors, cutaneous, non-cutaneous melanoma, HER2 negative and HER2 positive breast cancer, triple negative breast cancer, metastatic colorectal cancer and metastatic uveal melanoma. The therapy comprise of tumor-infiltrating lymphocytes (TILs). It is developed based on TIDAL platform. It is administered through parenteral route.
Turnstone Biologics overview
Turnstone Biologics, is a clinical stage biotech company that developing breakthrough cancer immunotherapies. The company is headquartered in Canada.
For a complete picture of TIDAL-01’s drug-specific PTSR and LoA scores, buy the report here.